Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies
Metrics: PDF 1216 views | HTML 2837 views | ?
Haibo Ni1,*, Qin Rui2,*, Xiaojue Zhu2,*, Zhenquan Yu3, Rong Gao1 and Huixiang Liu1
1Department of Neurosurgery, The First People’s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China
2Department of Laboratory, The First People’s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China
3Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
*These authors have contributed equally to this work
Huixiang Liu, email: [email protected]
Rong Gao, email: [email protected]
Keywords: antihypertensive drug, breast cancer, meta-analysis, cancer prevention, epidemiology
Received: July 20, 2016 Accepted: April 14, 2017 Published: July 10, 2017
We conducted a meta-analysis of observational studies to examine the hypothesized association between breast cancer and antihypertensive drug (AHT) use. Fixed- or random- effect models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all AHTs and individual classes (i.e., angiotensin-converting enzyme inhibitors, [ACEi]; angiotensin-receptor blockers, [ARBs]; calcium channel blockers, [CCBs]; beta-blockers, [BBs], and diuretics). Twenty-one studies with 3,116,266 participants were included. Overall, AHT use was not significantly associated with breast cancer risk (RR = 1.02, 95% CI: 0.98-1.06), and no consistent association was found for specific AHT classes with pooled RRs of 1.02 (95% CI: 0.96-1.09) for BBs, 1.07 (95% CI: 0.99-1.16) for CCBs, 0.99 (95% CI: 0.93-1.05) for ACEi/ARBs, and 1.05 (95% CI: 0.99-1.12) for diuretics. When stratified by duration of use, there was a significantly reduced breast cancer risk for ACEi/ARB use ≥10 years (RR = 0.80, 95% CI: 0.67-0.95). Although there was no significant association between AHT use and breast cancer risk, there was a possible beneficial effect was found for long-term ACEi/ARB. Large, randomized controlled trials with long-term follow-up are needed to further test the effect of these medications on breast cancer risk.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.